Approval · Notice of Compliance 5219 · 1995
TAZOCIN: Notice of Compliance 5219
Issued June 22, 1995
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 5219
- Date
- June 22, 1995
- Company
- Wyeth-Ayerst Canada Inc.St. Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Therapeutic class
- ANTIBIOTIC, ß-LACTAMASE INHIBITOR
Products in this notice
Medicinal ingredients
- PIPERACILLIN SODIUM 2 G per VIAL
- TAZOBACTAM SODIUM 250 MG per VIAL
- PIPERACILLIN SODIUM 3 G per VIAL
- TAZOBACTAM SODIUM 375 MG per VIAL
- PIPERACILLIN SODIUM 4 G per VIAL
- TAZOBACTAM SODIUM 500 MG per VIAL